Immunis

Immunis is a private, clinical-stage biotech pioneering a first-in-class, multi-active biologic approach to longevity medicine. Its core technology is a proprietary stem cell-derived secretome, a complex mixture of regenerative factors designed to address multiple pathways involved in age-related tissue decline. The company's lead program, IMM01-STEM, is in clinical development for sarcopenia and related conditions, targeting the vast and growing market for interventions that preserve muscle health and independence in aging populations. As a pre-revenue entity, Immunis is focused on advancing its clinical pipeline through investor funding and strategic partnerships.

Proprietary stem cell-derived secretome platform producing a complex biologic (IMM01-STEM) containing regenerative factors, proteins, and vesicles that modulate multiple signaling pathways involved in tissue repair and aging.

The field for sarcopenia therapeutics is competitive, with large pharma and biotechs exploring modalities like myostatin inhibitors, SARMs, and other anabolic agents. Immunis differentiates itself with a natural, multi-factor biologic approach aimed at modifying the underlying aged tissue microenvironment. It also competes within the broader longevity biotech sector, where numerous startups are targeting various hallmarks of aging.